Fungal infection of the scalp. Fungal infections, such as: tinea mycosis, leggermosis, athlete's foot in cases where oral treatment is justified due to the location, severity or extent of infection. Onychomycosis caused by dermatophytes. Terbinafine in the form of tabl. used orally is not effective in the treatment of Miscanthus dandruff. Official local guidelines on the correct use and prescription of antifungal drugs should be taken into account.
Composition:
1 tabl contains 250 mg of terbinafine hydrochloride.
Action:
A drug from the group of allylamines. It exerts antifungal activity as a result of inhibition of the early stage of ergosterol biosynthesis in fungal cells. It works on dermatophytes (Epidermophyton floccosum, Trichophyton mentagrophytes, T. tonsurans, Microsporum canis), some dimorphic fungi and yeasts (Candida spp., Cryptococcus neoformans). Absorption is greater after administration of the drug with food. When administered orally, it is well absorbed and quickly penetrates into the stratum corneum, tallow, hair. Plasma protein binding is 99%. Terbinafine also passes through the nail plate, where its therapeutic concentrations last long after treatment. It is rapidly and extensively metabolised in the liver. The drug and its metabolites are mainly excreted in the urine. T0,5 in the blood is 17 h.
Contraindications:
Hypersensitivity to terbinafine or any of the other ingredients. Severe kidney or liver problems.
Precautions:
Use with caution in patients with renal impairment (creatinine clearance <50 ml / min), psoriasis or those receiving tricyclic antidepressants, β-blockers, selective serotonin reuptake inhibitors, type B MAO inhibitors. There are no data on the safety and efficacy of terbinafine children under 2 years old.
Pregnancy and lactation:
Use only in case of extreme necessity. Do not use during breast-feeding.
Side effects:
Common: abdominal bloating, loss of appetite, dyspepsia, nausea, mild abdominal pain or diarrhea; rash, urticaria; headaches, malaise and fatigue; joint and muscle pain (these symptoms occur as elements of hypersensitivity reactions together with allergic skin reactions). Uncommon: dysfunction or loss of taste (usually resolving within a few weeks or months after discontinuation of treatment). Rare: severe skin reactions (eg Stevens-Johnson syndrome, toxic epidermal necrolysis or anaphylactic reactions), hypersensitivity to light; paresthesia, weakness of feeling, dizziness; liver and bile duct disorders usually in the form of cholestasis, in rare cases in the form of liver failure; anaphylactic reactions and serum sickness. Very rare: exacerbation of psoriasis; haematological disorders such as neutropenia, thrombocytopenia and agranulocytosis; occurrence or exacerbation of skin lupus or systemic lupus erythematosus; depression, anxiety; irregular menstruation and intermenstrual bleeding.
Dosage:
Orally. Adults 250 mg once a day. Children> 2 years old, m.c. 15-20 kg: 62.5 mg once a day; children about m.c. 20-40 kg: 125 mg once a day; children about m.c. above 40 kg: 250 mg once a day. Patients with renal insufficiency are given half the dose. Duration of treatment: 2-6 weeks in tinea pedis (interdigital, plantar / moccasin type); 2-4 weeks in tinea or tinea mycosis; 4 weeks in onychomycosis of the scalp; 6-12 weeks (sometimes up to 6 months or more) in onychomycosis of the hands and feet.
(C)
